Ipsen in neurology collaboration with Singapore agency

16 May 2016

Ipsen (Euronext: IPN) is partnering with the Institute of Molecular and Cell Biology (IMCB), a research body under the aegis of Singapore’s Agency for Science, Technology and Research (A*STAR), to study the intracellular trafficking of botulinum neurotoxins (BoNTs) within neurons.

A*STAR is Singapore's lead public sector agency that spearheads economic-oriented research to advance scientific discovery and develop innovative technology. It does so in collaboration with partners in both the public and private sectors.

The collaboration seeks to combine the French drugmaker’s expertise in BoNT recombinant engineering and biology, with IMCB's knowledge in the fields of membrane and toxin trafficking and RNA interference screening.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK